| __timestamp | Gilead Sciences, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 305409000 |
| Thursday, January 1, 2015 | 3426000000 | 377080000 |
| Friday, January 1, 2016 | 3398000000 | 432829000 |
| Sunday, January 1, 2017 | 3878000000 | 496079000 |
| Monday, January 1, 2018 | 4056000000 | 557616000 |
| Tuesday, January 1, 2019 | 4381000000 | 658498000 |
| Wednesday, January 1, 2020 | 5151000000 | 770456000 |
| Friday, January 1, 2021 | 5246000000 | 840100000 |
| Saturday, January 1, 2022 | 5673000000 | 944700000 |
| Sunday, January 1, 2023 | 6090000000 | 1136600000 |
| Monday, January 1, 2024 | 6091000000 | 1464300000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, operational efficiency is key. Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated, two industry leaders, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Gilead's SG&A expenses surged by over 100%, reaching approximately $6.1 billion in 2023. This reflects a strategic expansion and increased investment in operational capabilities. In contrast, Vertex Pharmaceuticals, while also increasing its SG&A expenses, maintained a more conservative growth of around 270%, peaking at $1.14 billion in 2023. This disparity highlights different strategic approaches: Gilead's aggressive scaling versus Vertex's steady growth. As these companies continue to evolve, their SG&A trends offer valuable insights into their operational priorities and market strategies.
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared